Form 4: Fennec Pharmaceuticals CFO's Restricted Stock Vesting
Insider Transaction Report
Fennec Pharmaceuticals Inc.'s Chief Financial Officer, Robert Andrade, acquired 2,431 common shares through the vesting of previously awarded restricted stock.
Summary
- Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals Inc. (FENC), acquired 2,431 common shares.
- The transaction occurred on July 31, 2025.
- These shares were released from restrictions related to awards granted on March 31, 2023, and May 16, 2024.
- The acquisition price per share was $0, indicating a non-cash transaction such as a stock award vesting.
- Following this transaction, Robert Andrade directly beneficially owns 165,813 common shares.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive as it represents a routine vesting of shares for a key executive, aligning their interests with shareholders. It is not highly impactful but indicates stability in compensation.
Positives
- The vesting of restricted shares for the Chief Financial Officer aligns management's interests with those of shareholders.
- The transaction represents a routine compensation event, indicating stability in executive compensation structure.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance.
Industry Context
This filing details a routine insider transaction related to executive compensation, which is common across all industries and does not reflect broader industry trends or competitive dynamics.
Related Party Transactions
- The acquisition of 2,431 common shares by Robert Andrade, the Chief Financial Officer, represents a compensation-related transaction from the issuer, Fennec Pharmaceuticals Inc.
Stakeholder Impact
- Shareholders: The vesting of shares for the CFO can be viewed positively as it increases management's direct ownership in the company, aligning their financial interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Date of initial restricted share award. |
| 05/16/2024 | Date of additional restricted share award. |
| 07/31/2025 | Date of transaction where 2,431 common shares were acquired through vesting. |
| 08/01/2025 | Date the Form 4 was signed by Robert Andrade. |
Keywords
Fennec Pharmaceuticals, FENC, Form 4, insider transaction, stock award, CFO, equity, restricted stock, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.